These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27802454)

  • 1. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
    Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
    Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
    Hidalgo M; Plaza C; Musteanu M; Illei P; Brachmann CB; Heise C; Pierce D; Lopez-Casas PP; Menendez C; Tabernero J; Romano A; Wei X; Lopez-Rios F; Von Hoff DD
    Clin Cancer Res; 2015 Nov; 21(21):4811-8. PubMed ID: 26169969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
    Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
    Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
    Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
    Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal expression of SPARC in pancreatic adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
    Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
    Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.
    Arqueros C; Salazar J; Arranz MJ; Sebio A; Mora J; Sullivan I; Tobeña M; Martín-Richard M; Barnadas A; Baiget M; Páez D
    Med Oncol; 2017 Aug; 34(8):136. PubMed ID: 28687963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nab-paclitaxel].
    Lopez-Trabada Ataz D; Dumont S; André T
    Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
    Schneeweiss A; Seitz J; Smetanay K; Schuetz F; Jaeger D; Bachinger A; Zorn M; Sinn HP; Marmé F
    Anticancer Res; 2014 Nov; 34(11):6609-15. PubMed ID: 25368265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
    Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
    EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of SPARC expression in pancreatic cancer progression and patient survival.
    Gundewar C; Sasor A; Hilmersson KS; Andersson R; Ansari D
    Scand J Gastroenterol; 2015; 50(9):1170-4. PubMed ID: 25765175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
    Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
    J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis.
    Zhou X; Zhang L; Qierang C; Huang M; Yang X; Li L; Jiang J
    Transl Cancer Res; 2021 Feb; 10(2):876-885. PubMed ID: 35116417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.
    Kim NI; Kim GE; Lee JS; Park MH
    Virchows Arch; 2017 Jan; 470(1):91-98. PubMed ID: 27909812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
    Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
    Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
    Neesse A; Michl P; Tuveson DA; Ellenrieder V
    Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.